Bruce Germer, MD
Ophthalmology · Metairie, LANPI 1780655258
Payments from drug & device makers
What this record shows
This record is dominated by gifts: $3,924 of the $5,746 with a category attached, or 68.3%. Carl Zeiss Meditec, Inc. accounts for 68.3% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $4,610 and has fallen 91.7% since, to $385 in 2025.
Across 69 payments — averaging $83.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$4K
- Genentech USA, Inc.$507
- Alimera Sciences, Inc.$256
- Regeneron Healthcare Solutions, Inc.$236
- Apellis Pharmaceuticals, Inc.$217
- AbbVie$192
- plus $414 from 8 others
What the payments were for
- Food & beverage$1,82232%
- Gifts$3,92468%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 1 | $3,924 |
| Genentech USA, Inc. | 19 | $507 |
| Alimera Sciences, Inc. | 9 | $256 |
| Regeneron Healthcare Solutions, Inc. | 9 | $236 |
| Apellis Pharmaceuticals, Inc. | 9 | $217 |
| AbbVie(2 entities) | 4 | $192 |
| Astellas Pharma US Inc | 6 | $148 |
| Novartis | 4 | $67 |
| Glaukos Corporation | 1 | $59 |
| Biogen | 2 | $42 |
| Mallinckrodt Enterprises LLC | 2 | $42 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Eyepoint US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPMI Lumera$3,924
- Iluvien$134
- VABYSMO$132
- OZURDEX$125
How this compares
$5,746 in reported general payments places this provider in the 80th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 109 | $5,392 |
| Ketorolac Tromethamine | 71 | $2,028 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 53 | $653 |
| Timolol Maleate | 27 | $127 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 11 | $123 |
| Latanoprost | 11 | $60 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Metairie
- Ethan SternMetairie$16K
- John FrisbeeMetairie$14K
- Benjamin GuidryMetairie$9K
- Scott LanouxMetairie$8K
- Tyler GoffMetairie$7K
- John BoyleMetairie$7K
- Nicholas FrisardMetairie$7K
- Brandon DavisMetairie$7K
- Henry HaleyMetairie$7K
- Owen LacourMetairie$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.